Maximum human lifespan has already been reached

A study published online today in Nature by Albert Einstein College of Medicine scientists suggests that it may not be possible to extend the human life span beyond the ages already attained by the oldest people on record. Since the 19th century, average life expectancy has risen almost continuously thanks to improvements in public health, diet, the environment and other areas. On average, for example, U.S. babies born today can expect to live nearly until age 79 compared with an average life expectancy of only 47 for Americans born in 1900. Since the 1970s, the maximum duration of life - the age to which the oldest people live - has also risen. But according to the Einstein researchers, this upward arc for maximal lifespan has a ceiling - and we've already touched it.

"Demographers as well as biologists have contended there is no reason to think that the ongoing increase in maximum lifespan will end soon," said senior author Jan Vijg, Ph.D., professor and chair of genetics, the Lola and Saul Kramer Chair in Molecular Genetics, and professor of ophthalmology & visual sciences at Einstein. "But our data strongly suggest that it has already been attained and that this happened in the 1990s."

Dr. Vijg and his colleagues analyzed data from the Human Mortality Database, which compiles mortality and population data from more than 40 countries. Since 1900, those countries generally show a decline in late-life mortality: The fraction of each birth cohort (i.e., people born in a particular year) who survive to old age (defined as 70 and up) increased with their calendar year of birth, pointing toward a continuing increase in average life expectancy.

But when the researchers looked at survival improvements since 1900 for people aged 100 and above, they found that gains in survival peaked at around 100 and then declined rapidly, regardless of the year people were born. "This finding indicates diminishing gains in reducing late-life mortality and a possible limit to human lifespan," said Dr. Vijg.

He and his colleagues then looked at "maximum reported age at death" data from the International Database on Longevity. They focused on people verified as living to age 110 or older between 1968 and 2006 in the four countries (the U.S., France, Japan and the U.K.) with the largest number of long-lived individuals. Age at death for these supercentenarians increased rapidly between the 1970s and early 1990s but reached a plateau around 1995 - further evidence for a lifespan limit. This plateau, the researchers note, occurred close to 1997 - the year of death of 122-year-old French woman Jeanne Calment, who achieved the maximum documented lifespan of any person in history.

Using maximum-reported-age-at-death data, the Einstein researchers put the average maximum human life span at 115 years - a calculation allowing for record-oldest individuals occasionally living longer or shorter than 115 years. (Jeanne Calment, they concluded, was a statistical outlier.) Finally, the researchers calculated that the probability in a given year of seeing one person live to 125 anywhere in the world is less than 1 in 10,000.

"Further progress against infectious and chronic diseases may continue boosting average life expectancy, but not maximum lifespan," said Dr. Vijg. "While it's conceivable that therapeutic breakthroughs might extend human longevity beyond the limits we've calculated, such advances would need to overwhelm the many genetic variants that appear to collectively determine the human lifespan. Perhaps resources now being spent to increase lifespan should instead go to lengthening healthspan - the duration of old age spent in good health."

The study was supported by National Institutes of Health grants AG017242 and AG047200, the Albert Einstein College of Medicine Institute for Aging Research/Nathan Shock Center and the Paul F. Glenn Center for the Biology of Human Aging at Albert Einstein College of Medicine.

Dong X, Milholland B, Vijg J.
Evidence for a limit to human lifespan.
Nature. 2016 Oct 5. doi: 10.1038/nature19793.

Most Popular Now

Novartis research shows technology talent increasi…

Novartis revealed the healthcare and pharma industry has emerged as a desired career destination for tech talent during the COVID-19 pandemic, in the Powerful Pairing res...

GSK COVID-19 vaccine development collaboration wit…

GSK's scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical trials. Clover announced the initiati...

Lilly begins world's first study of a potential CO…

Eli Lilly and Company (NYSE: LLY) announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19. This inve...

Sanofi invests to make France its world class cent…

Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in respon...

Low-cost dexamethasone reduces death by up to one …

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for C...

Super-potent human antibodies protect against COVI…

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus ...

Sanofi and Translate Bio expand collaboration to d…

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have agreed to ...

AstraZeneca to supply Europe with up to 400 millio…

AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 milli...

Gilead announces results from Phase 3 Trial of rem…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label st...

Up to 45 percent of SARS-CoV-2 infections may be a…

An extraordinary percentage of people infected by the virus behind the ongoing deadly COVID-19 pandemic never show symptoms of the disease, according to the results of a ...

Bayer supports "The Challenge Initiative…

Today Bayer announced the support of "The Challenge Initiative" ("TCI" hereafter) with a payment of 10 million USD. Hosted at the Johns Hopkins Bloomberg School of Public...

Researchers identify potent antibody cocktail to t…

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail...